http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 17:17:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Greenway+Nicola+Deidre+Petal/26885587.html si-local-file:///var/storage/secattach/20260806/26885587.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Greenway+Nicola+Deidre+Petal/26885587.html Thu, 06 Aug 2026 17:17:00 -0400 4502 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Greenway+Nicola+Deidre+Petal/26885587.html si-local-file:///var/storage/secattach/20260806/26885587.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Greenway+Nicola+Deidre+Petal/26885587.html Thu, 06 Aug 2026 17:17:00 -0400 4502 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Greenway+Nicola+Deidre+Petal/26885587.html si-local-file:///var/storage/secattach/20260806/26885587.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Greenway+Nicola+Deidre+Petal/26885587.html Thu, 06 Aug 2026 17:17:00 -0400 4502 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Aug+05/26877524.html si-local-file:///var/storage/secattach/20260806/26877524.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Aug+05/26877524.html Thu, 06 Aug 2026 06:05:00 -0400 4502 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Aug+05/26877524.html si-local-file:///var/storage/secattach/20260806/26877524.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Aug+05/26877524.html Thu, 06 Aug 2026 06:05:00 -0400 4502 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Aug+05/26877524.html si-local-file:///var/storage/secattach/20260806/26877524.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Aug+05/26877524.html Thu, 06 Aug 2026 06:05:00 -0400 4502 O.05065998 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html <p>Takeda (TSE: 4502 / NYSE: TAK) announced that the U.S. Food and Drug Administration has approved Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults.</p> <p>Narcolepsy type 1 is a rare, chronic neurological disease caused by a loss of orexin and affects an estimated 120,000 people in the U.S. Symptoms include excessive daytime sleepiness, cataplexy, cognitive impairment, and disrupted nighttime sleep.</p> <p>According to the company, Orzeyful is the only medicine approved in the U.S. indicated to treat the disease rather than individual symptoms. The drug has also received regulatory approval in China.</p> <p>The FDA approval http://www.streetinsider.com/FDA/FDA+approves+Takeda%27s+Orzeyful+for+narcolepsy+type+1+in+adults/26876321.html Wed, 05 Aug 2026 18:10:14 -0400 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html <ul class="bwlistdisc"> <li> Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo </li> <li> As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms </li> <li> Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process </li> </ul> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK%29&amp;index=1&amp;md5=f500e5ccb052376c8b2918c5896a8b17" shape="rect">TSE:4502/NYSE:TAK)</a> announced that the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms&amp;esheet=54584583&amp;newsitemid=20260805760759&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+approved&amp;index=2&amp;md5=70f9dc2b11f6317368f0a37833f9c049" shape="rect">U.S. Food and Drug Administration (FDA) approved</a> ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Takeda%E2%80%99s+ORZEYFUL%E2%84%A2+%28oveporexton%29%2C+the+First+and+Only+Medicine+to+Treat+the+Underlying+Cause+of+Narcolepsy+Type+1/26876319.html Wed, 05 Aug 2026 18:10:00 -0400 4502 4502 A.06822034 A.37042239 O.00987337 O.05065998 O.20026344 O.21062042 TAK